Here comes a more precise version of CRISPR
The first company to go after human disease with a more precise genome-editing tool called base editing, Beam Therapeutics, launched today.
The technology: DNA is made up of lots of combinations of base letters (we know them as A, C, G, and T). Base editing, developed by Harvard chemical biologist and Beam cofounder David Liu, is designed to target just one base out of billions within the genome.
CRISPR 2.0: The traditional CRISPR system cuts a whole gene—a sequence of different base letters—to make a break in DNA’s double-helix structure. Liu’s base editors directly convert a single base into another, changing the gene from the mutated to the corrected form. Last year, researchers in China reported that they used base editing to snip disease out of a human embryo, but the approach hasn’t been tried in a person yet.
Treating disease: Beam, which is also cofounded by CRISPR pioneer Feng Zhang, hasn’t said what diseases it will focus on. But in a press release, it said that base editing could be used to treat some of the most devastating genetic disorders.
Deep Dive
Biotechnology and health
This baby with a head camera helped teach an AI how kids learn language
A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.
An AI-driven “factory of drugs” claims to have hit a big milestone
Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology
How scientists traced a mysterious covid case back to six toilets
When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.
The next generation of mRNA vaccines is on its way
Adding a photocopier gene to mRNA vaccines could make them last longer and curb side effects.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.